Discover how to maximise the quality of vaccines through the removal of host cell residuals from Dr Wu Ke, President and Founder, Shanghai BravoBio Co, Ltd, China. He will be speaking at Biologic Manufacturing World Asia 2012, part of a series of conferences in the 5th Annual BioPharma Asia Convention 2012, held on 19-22 March at Marina Bay Sands, Singapore.
Dr Wu has 23 years of experiences in biopharm industry and has successfully developed 7 products approved by SFDA and marketed in China. Dr. Wu was Executive President of Shanghai Zerun Biotechnology, Wison Group, in charge of management of QA/QC, Manufacture, Engineering and Maintenance, Regulatory Affairs, Marketing. He also has extensive experience in R&D management, business development, technology transfer, etc. Prior to joining Zerun/Wison, he was Director of R&D in Wuhan Institute of Biological Products, China National Biotec Group (CNBG). Dr. Wu hold a PhD degree in Immunology and also has Certificates of Senior Management from China Europe International Business School (CEIBS) and Cheung Kong Graduate School of Business (CKGSB).
He will be speaking on the following topics:
1. Improving vaccine products through the removal of residual host cell DNA and proteins to minimize adverse reaction cases
2. Examining progress of current processes in removing residual host cell DNA and proteins
3. Enhancing quality control standards and pharmacopeia to align with the demand for better vaccine products